XML 48 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Collaborative Research and Development Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 12 Months Ended
Jun. 30, 2010
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Mar. 31, 2018
Mitsubishi Tanabe            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems]            
Up-front license fees         $ 30,000,000  
Collaborative agreement maximum additional payment to receive         85,000,000  
Patent rights period   The longer of ten years or the life of the related patent rights.        
Collaborative arrangement right description   Under the terms of the agreement, Mitsubishi Tanabe is responsible for all third-party development, marketing and commercialization costs in Japan and other select Asian markets and the Company would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties. There are no performance, cancellation, termination, or refund provisions in the agreement that would have a material financial consequence to the Company. The Company does not directly control when event-based payments will be achieved or when royalty payments will begin. Mitsubishi Tanabe may terminate the agreement at its discretion upon 180 days written notice to the Company. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to the Company.        
Collaboration termination notice period   180 days        
Revenues recognized under collaboration agreement   $ 0 $ 15,000,000 $ 0 19,800,000  
Deferred revenues under collaboration         $ 10,200,000  
Mitsubishi Tanabe | Topic 606            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems]            
Clinical trial cost   12,000,000        
Up-front consideration received   $ 30,000,000        
AbbVie            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems]            
Up-front license fees $ 75,000,000          
Patent rights period   Ten years or the life of the related patent rights.        
Collaborative arrangement right description   The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.        
Collaboration termination notice period   180 days        
Revenues recognized under collaboration agreement   $ 40,000,000 30,000,000 $ 15,000,000    
Sales-based royalties   1,600,000        
AbbVie | Development and Regulatory Milestone Payments            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems]            
Collaborative agreement maximum additional payment to receive   480,000,000        
Collaborative agreement payment received   115,000,000        
AbbVie | Commercial Milestone Payments            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems]            
Collaborative agreement maximum additional payment to receive   50,000,000        
AbbVie | Topic 606            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems]            
Up-front consideration received   $ 75,000,000        
B I A L            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems]            
Up-front license fees     $ (30,000,000)      
License agreement date     Feb. 09, 2017      
B I A L | Event Based Milestones            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems]            
Milestone payables           $ 10,000,000
B I A L | Regulatory Approval and Net Sales Milestones            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems]            
Milestone payables           105,000,000
B I A L | Regulatory and Clinical Results and FDA Acceptance Milestones            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [LineItems]            
Milestone payables           $ 10,000,000